International Journal of Cancer Management

Published by: Kowsar

Ectopic Expression of miRNA-21 and miRNA-205 in Non-Small Cell Lung Cancer

Seyedeh Afrooz Azimi ORCID 1 , Hamid Reza Sadegh Nia 2 , Alireza Mosavi Jarrahi 3 , Hamid Reza Jamaati 4 , Mehdi Kazempour Dizaji 5 , Hossein Dargahi 6 , Naghmeh Bahrami 7 , 8 , Alireza Pasdar 1 , 9 , Adnan Khosravi 10 , Naeim Bahrami 11 , Shadi Daghighi 11 and Abdolreza Mohamadnia ORCID 4 , 12 , *
Authors Information
1 Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department Social Medicine, The Cancer Institute Research Center, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Biostatistics Department, Mycobacteriology Research Center, National Research Institute of Tuberculosis and lung Diseases , Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Management Sciences and Health Economic Department, Health Information Management Research Center, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
7 Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran
8 Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
9 Division of Applied Medicine, Medical School, University of Aberdeen, Forester Hill, Aberdeen, United Kingdom
10 Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
11 Department of Radiology, University of California San Diego, San Diego, Unites States
12 Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: January 31, 2019, 12 (1); e85456
  • Published Online: January 19, 2019
  • Article Type: Research Article
  • Received: October 16, 2018
  • Revised: January 8, 2019
  • Accepted: January 9, 2019
  • DOI: 10.5812/ijcm.85456

How to Cite: Azimi S A, Sadegh Nia H R, Mosavi Jarrahi A, Jamaati H R, Kazempour Dizaji M, et al. Ectopic Expression of miRNA-21 and miRNA-205 in Non-Small Cell Lung Cancer, Int J Cancer Manag. 2019 ; 12(1):e85456. doi: 10.5812/ijcm.85456.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: Clinical implications. Thorax. 2003;58(10):892-900. doi: 10.1136/thorax.58.10.892. [PubMed: 14514947]. [PubMed Central: PMC1746489].
  • 2. Yu H, Huang X, Zhu Z, Hu Y, Ou W, Zhang L, et al. Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma. Chin J Cancer Res. 2014;26(1):89-94. doi: 10.3978/j.issn.1000-9604.2014.02.04. [PubMed: 24653630]. [PubMed Central: PMC3937746].
  • 3. Yilmaz A, Damadoglu E, Salturk C, Okur E, Tuncer LY, Halezeroglu S. Delays in the diagnosis and treatment of primary lung cancer: Are longer delays associated with advanced pathological stage? Ups J Med Sci. 2008;113(3):287-96. doi: 10.3109/2000-1967-236. [PubMed: 18991241].
  • 4. Custodio A, Mendez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treat Rev. 2012;38(1):36-53. doi: 10.1016/j.ctrv.2011.04.001. [PubMed: 21592673].
  • 5. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol. 2010;5(12 Suppl 6):S434-54. doi: 10.1097/01.JTO.0000391362.10517.1f. [PubMed: 21102235].
  • 6. Xu WJ, Su XL, Liu M. miRNA and cancer. J Dis Monit Control. 2013;5:25.
  • 7. Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, et al. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 2013;8(3). e60317. doi: 10.1371/journal.pone.0060317. [PubMed: 23555954]. [PubMed Central: PMC3608584].
  • 8. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011;676:3-22. doi: 10.1007/978-1-60761-863-8_1. [PubMed: 20931386].
  • 9. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91(4):579-87. doi: 10.1038/labinvest.2010.194. [PubMed: 21116241]. [PubMed Central: PMC3130190].
  • 10. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189-98. doi: 10.1016/j.ccr.2006.01.025. [PubMed: 16530703].
  • 11. Hummel R, Hussey DJ, Haier J. MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46(2):298-311. doi: 10.1016/j.ejca.2009.10.027. [PubMed: 19948396].
  • 12. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009;106(29):12085-90. doi: 10.1073/pnas.0905234106. [PubMed: 19597153]. [PubMed Central: PMC2715493].
  • 13. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest. 2010;90(2):144-55. doi: 10.1038/labinvest.2009.126. [PubMed: 20048743].
  • 14. Li X, Xin S, He Z, Che X, Wang J, Xiao X, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem. 2014;33(6):1631-42. doi: 10.1159/000362946. [PubMed: 24902663].
  • 15. Tabruyn SP, Hansen S, Ojeda-Fernandez ML, Bovy N, Zarrabeitia R, Recio-Poveda L, et al. MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. 2013;16(4):877-87. doi: 10.1007/s10456-013-9362-9. [PubMed: 23800974].
  • 16. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-33. doi: 10.1158/0008-5472.CAN-05-0137. [PubMed: 16024602].
  • 17. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene. 2011;30(26):2975-85. doi: 10.1038/onc.2011.15. [PubMed: 21317927]. [PubMed Central: PMC3134876].
  • 18. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014;18(3):371-90. doi: 10.1111/jcmm.12236. [PubMed: 24533657]. [PubMed Central: PMC3943687].
  • 19. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003-8. doi: 10.1073/pnas.1019055108. [PubMed: 21383194]. [PubMed Central: PMC3064324].
  • 20. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. Corrigendum: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2014;17(1):104. doi: 10.1038/ncb3074.
  • 21. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3(11). e3694. doi: 10.1371/journal.pone.0003694. [PubMed: 19002258]. [PubMed Central: PMC2577891].
  • 22. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-8. doi: 10.1073/pnas.0804549105. [PubMed: 18663219]. [PubMed Central: PMC2492472].
  • 23. Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. J Clin Oncol. 2014;32(8):768-73. doi: 10.1200/JCO.2013.50.4357. [PubMed: 24419137]. [PubMed Central: PMC4876348].
  • 24. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC. The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. Mol Oncol. 2014;8(4):819-29. doi: 10.1016/j.molonc.2014.02.009. [PubMed: 24656978]. [PubMed Central: PMC5528532].
  • 25. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 2013;43(1):307-14. doi: 10.3892/ijo.2013.1915. [PubMed: 23612742].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments